In 2014, B. Braun CeGaT, LLC, was established as a partnership between B. Braun Medical and CeGaT to offer advanced molecular diagnostic services to US-based health care providers. With B. Braun’s proven history of enhancing patient care and safety and CeGaT’s pioneering advancements in sequencing-based diagnostics, the joint venture is well positioned to bring personalized medicine to the clinical setting. Our services are aimed at enabling physicians to precisely determine the molecular cause of an individual’s disease. Using this information, a specific diagnosis can be made, and the optimal course of treatment can be selected based on the patient’s unique genetic profile.
It is our goal to serve the US health care market with a dedicated team and the highest possible standard in molecular diagnostics.
President/Managing Board of B. Braun CeGaT, LLC
Saskia Biskup about CeGaT
CeGaT is a leading global provider of genetic diagnostics and mutation-related disease analyses. By pioneering the approach of combining genetic diagnostics with high-throughput sequencing, CeGaT was the first company to develop the so-called Diagnostic Panels. These Diagnostic Panels allowed for the first time ever mapping and analyzing all genes associated with a certain disease. Meanwhile, we launched Diagnostic Panels for a broad range of disease categories. Therefore, CeGaT is able to dramatically improve the accuracy and speed of diagnosis, leading to more targeted and effective treatments, better quality of patient care, and significant cost reduction to the health care industry.
Since its founding in 2009, CeGaT has been the recipient of multiple awards including German Founders Award for Best Start-Up Company 2011, “Entrepreneur of the Year” in 2013, and “Service Provider of the Year 2014” by the State of Baden-Württemberg.
We are here to assist. Whether you’re interested in the investigation of gene sequencing or DNA diagnostics, we will help you every step of the way.
Saskia Biskup, MD, PhD Specialist in Human Genetics
Managing Director of CeGaT
Genetic Diagnostics at its Highest Level
Since its founding in 2009, CeGaT has strived to attract the strongest, most qualified professionals and today employs more than 100 highly competent physicians, scientists, bioinformaticians, and technical assistants, all of them working together as a cohesive team.
In addition to staff development, CeGaT has invested in the most advanced sequencing technology (Illumina NovaSeq 6000 and MiSeq) and associated equipment (Automatic blood prep, Fragment Analyzer, 5 pipetting robots, 2 high-performance computers).
Through advanced technology and expertise, CeGaT has grown explosively by continually refining and improving the quality of genetic sequencing and data analysis. As of 2014, CeGaT is growing its revenue at a rate that exceeds 100 percent per year.
Accreditation Certificates of CeGaT
DIN EN ISO 15189 Certificate of Accreditation 2016
Annex to the DIN EN ISO 15189 Accreditation Certificate 2016